This is a single-center, open-label, randomized, single-dose, parallel, Phase 1, 4-arm study designed to determine the bioequivalence and investigate the safety and tolerability profiles of subcutaneous amlitelimab delivered by 2 different devices at 2 different total doses in healthy adult participants.
Protocol Amendment History
5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2025-08-21; most recent amendment 2026-04-15.
Status change: Active, Not Recruiting → Completed2026-04-15
Status change: Recruiting → Active, Not Recruiting2025-12-04
Status change: Not Yet Recruiting → Recruiting2025-09-18